How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

7,563 results for

Pharmaceutical Representative

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

21. Novel Synthetic Opioids in Counterfeit Pharmaceuticals and Other Illicit Street Drugs

Novel Synthetic Opioids in Counterfeit Pharmaceuticals and Other Illicit Street Drugs www.ccsa.ca • www.cclt.ca CCENDU Bulletin, June 2016 Canadian Centre on Substance Abuse • Centre canadien de lutte contre les toxicomanies Page 1 CCENDU Bulletin Novel Synthetic Opioids in Counterfeit Pharmaceuticals and Other Illicit Street Drugs Summary ? Counterfeit pharmaceuticals are fake products manufactured illegally in clandestine labs. They are designed to look like legitimate pharmaceuticals. ? Sale (...) of counterfeit pharmaceuticals in the illicit market are becoming more frequent. In the United States and Canada there have been reports of counterfeit OxyContin® tablets, Percocet® tablets, Xanax® tablets, and Norco® tablets. These tablets often contain a synthetic opioid different from the active substance users believe is present. ? Novel synthetic opioids that have been used in these products are fentanyl and fentanyl analogues. Other substances that have been used or might be used include W-18,* U-47700

2016 Canadian Centre on Substance Abuse

22. Pharmaceutical policies: effects of cap and co-payment on rational use of medicines. (Full text)

Pharmaceutical policies: effects of cap and co-payment on rational use of medicines. Growing expenditures on prescription medicines represent a major challenge to many health systems. Cap and co-payment policies are intended as an incentive to deter unnecessary or marginal utilisation, and to reduce third-party payer expenditures by shifting parts of the financial burden from insurers to patients, thus increasing their financial responsibility for prescription medicines. Direct patient payment

2015 Cochrane PubMed

23. Primary care behavioral interventions to prevent or reduce illicit drug use and nonmedical pharmaceutical use in children and adolescents: a systematic evidence review for the U.S. Preventive Services Task Force (Full text)

Primary care behavioral interventions to prevent or reduce illicit drug use and nonmedical pharmaceutical use in children and adolescents: a systematic evidence review for the U.S. Preventive Services Task Force Primary care behavioral interventions to prevent or reduce illicit drug use and nonmedical pharmaceutical use in children and adolescents: a systematic evidence review for the U.S. Preventive Services Task Force Primary care behavioral interventions to prevent or reduce illicit drug use (...) and nonmedical pharmaceutical use in children and adolescents: a systematic evidence review for the U.S. Preventive Services Task Force Patnode CD, O’Connor E, Rowland M, Burda BU, Perdue LA, Whitlock EP CRD summary The evidence on the effectiveness of primary care behavioral interventions in reducing drug use among adolescents was limited. Despite some concerns about the conduct of the review, the results reflect the evidence found and the conclusions appear appropriate. Authors' objectives To evaluate

2014 DARE. PubMed

24. "Partnerships" with pharmaceutical companies: treat with scepticism

journals, healthcare professionals’ organisations, the Association of the British Pharmaceutical Industry (ABPI) and English, Scottish and Welsh government representatives endorsed two sets of guidelines on the subject. Some outside observers were struck by how biased these guidelines are in favour of pharmaceutical companies, echoing their usual arguments, including: “medical sales representatives can be a useful resource for healthcare professionals”; “information about industry-sponsored trials (...) "Partnerships" with pharmaceutical companies: treat with scepticism Prescrire IN ENGLISH - Spotlight ''"Partnerships" with pharmaceutical companies: treat with scepticism'', 1 July 2014 {1} {1} {1} | | > > > "Partnerships" with pharmaceutical companies: treat with scepticism Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight "Partnerships

2014 Prescrire

25. EMA's new policy on access to clinical data: About to privatise pharmaceutical knowledge? The proof will be in the pudding

EMA's new policy on access to clinical data: About to privatise pharmaceutical knowledge? The proof will be in the pudding Prescrire IN ENGLISH - Topics - Advancing healthcare policy : Advancing healthcare policy in Europe: a chronological recap of actions, EMA's new policy on access to clinical data (6/2014) {1} {1} {1} | | > >

" href="/en/79/207/ReportList.aspx"> Advancing healthcare policy > > > EMA's new policy on access to clinical data (6/2014) Advancing healthcare policy Advancing (...) healthcare policy in Europe: a chronological recap of actions Advancing healthcare policy A recap of actions in 2014 EMA's new policy on access to clinical data: About to privatise pharmaceutical knowledge? The proof will be in the pudding (June 2014) Brussels, 24 June 2014 EMA's controversial policy on access to clinical data is to be adopted by mid-July 2014 while restrictive measures and legal loopholes are left unaddressed. AIM, ISDB, MiEF and the Nordic Cochrane Centre call on the EMA to not succomb

2014 Prescrire

26. Association Between Academic Medical Center Pharmaceutical Detailing Policies and Physician Prescribing. (Full text)

Association Between Academic Medical Center Pharmaceutical Detailing Policies and Physician Prescribing. In an effort to regulate physician conflicts of interest, some US academic medical centers (AMCs) enacted policies restricting pharmaceutical representative sales visits to physicians (known as detailing) between 2006 and 2012. Little is known about the effect of these policies on physician prescribing.To analyze the association between detailing policies enacted at AMCs and physician (...) of policies regulating pharmaceutical salesperson visits to attending physicians.The monthly within-drug class market share of prescriptions written by an individual physician for detailed and nondetailed drugs in 8 drug classes (lipid-lowering drugs, gastroesophageal reflux disease drugs, diabetes drugs, antihypertensive drugs, hypnotic drugs approved for the treatment of insomnia [sleep aids], attention-deficit/hyperactivity disorder drugs, antidepressant drugs, and antipsychotic drugs) comparing the 10

2017 JAMA PubMed

27. U.S. Emergency Department Visits Resulting From Nonmedical Use of Pharmaceuticals, 2016. (PubMed)

U.S. Emergency Department Visits Resulting From Nonmedical Use of Pharmaceuticals, 2016. National data on morbidity from nonmedical use of pharmaceuticals are limited. This study used nationally representative, public health surveillance data to characterize U.S. emergency department visits for acute harms from nonmedical use of pharmaceuticals and to guide prevention efforts.Data collected in 2016 from the National Electronic Injury Surveillance System-Cooperative Adverse Drug Event (...) Surveillance project were analyzed in 2018 to calculate national estimates of emergency department visits for harms from nonmedical use of pharmaceuticals.Based on 5,130 surveillance cases, there were an estimated 358,247 emergency department visits (95% CI=280,675, 435,819) in 2016 for harms from nonmedical use of pharmaceuticals and 41.1% resulted in hospitalization (95% CI=32.3%, 49.8%). One half (50.9%, 95% CI=46.6%, 55.3%) of estimated visits involved patients aged ≤34 years; more than one half

2019 American journal of preventive medicine

28. Pharmaceutical marketing strategies' influence on physicians' prescribing pattern in Lebanon: ethics, gifts, and samples. (Full text)

of the promotional tools tested were mostly or sometimes motivating physicians to prescribe promoted drugs. The major tools that physicians agreed to be mostly motivated by are visits of medical representatives and drug samples while sales calls made by pharmaceutical companies are the less influential tool. Regarding gift acceptance, this study demonstrated that physicians consider gifts' acceptance as a non-ethical practice. Results showed that most physicians use free samples to treat their patients. We (...) Pharmaceutical marketing strategies' influence on physicians' prescribing pattern in Lebanon: ethics, gifts, and samples. Drug companies rely on their marketing activities to influence physicians. Previous studies showed that pharmaceutical companies succeeded to manage physicians prescribing behavior in developed countries. However, very little studies investigated the impact of pharmaceutical marketing strategies on prescribing pattern in developing countries, middle-eastern countries

2019 BMC health services research PubMed

29. Top 10 most read in October: Physician-pharmaceutical industry interactions, systematic reviews and unpublished data, and polypharmacy and falls in older adults

study by Xie et al. , which examines the association between Proton Pump Inhibitors and the risk of all-cause mortality. New in at number five is a systematic review by Fickweiler et al. , exploring whether physicians’ interactions with pharmaceutical industry representatives impact on their attitude and prescribing habits. The researchers extracted and synthesised data from studies encompassing an assortment of study designs; they demonstrate that interactions with pharmaceutical industry (...) Top 10 most read in October: Physician-pharmaceutical industry interactions, systematic reviews and unpublished data, and polypharmacy and falls in older adults Top 10 most read in October: Physician-pharmaceutical industry interactions, systematic reviews and unpublished data, and polypharmacy and falls in older adults | BMJ Open by Four new entries, and two re-entries, made it into BMJ Open’s top 10 most read articles in October. Climbing back into the top position is a longitudinal cohort

2017 BMJ Open Blog

30. Fact Sheet: Non-pharmaceutical measures to prevent the transmission of influenza

Fact Sheet: Non-pharmaceutical measures to prevent the transmission of influenza NCCEH Fact Sheet: Non-pharmaceutical measures to prevent the transmission of in? uenza This fact sheet is for public health professionals. It provides a brief overview on speci? c non-pharmaceutical measures to be used in community settings. Such measures can prevent the spread of in? uenza by interrupting the transfer of viruses from objects or people through the use of personal protective equipment or changes (...) to behaviour. The content is primarily based on the NCCID article “Non-pharmaceutical measures to prevent in? uenza transmission: the evidence for individual protective measures” by Crabtree and Henry (see Additional Resources). What types of non- pharmaceutical measures are there? ? Hand hygiene: washing hands frequently, especially after coughing or sneezing, and using appropriate methods; ? Respiratory hygiene: covering the mouth and nose with a tissue or sleeve when coughing or sneezing; ? Fomite

2015 National Collaborating Centre for Environmental Health

31. The role of industry representatives in the endoscopy unit

performed at tertiary academic medical centers. Our ability to acquire, optimally utilize and maintain endoscopic accessories, devices, and equipment allows provision of high quality endoscopic procedures. Furthermore, the findings of endoscopy often dictate subsequent pharmacotherapy. Industry representatives, acting on behalf of the device, pharmaceutical, and equipment manufacturers, play an important role in helping us achieve this goal. This document was prepared because there is no formal guidance (...) . Representatives should not take videos or photographs during procedures. Types of industry representatives The types of industry representatives encountered in an endoscopy unit may be diverse and are listed in Table 1. The most common are the device or accessory sales representatives (referred to here as product representative). Endoscope or other major equipment sales representatives, pharmaceutical representatives, product specialists, market development managers, scientific liaisons, and members of senior

2015 American Society for Gastrointestinal Endoscopy

32. HRS/ACC/AHA Expert Consensus Statement on the Use of Implantable Cardioverter-Defibrillator Therapy in Patients Who Are Not Included or Not Well Represented in Clinical Trials

HRS/ACC/AHA Expert Consensus Statement on the Use of Implantable Cardioverter-Defibrillator Therapy in Patients Who Are Not Included or Not Well Represented in Clinical Trials HRS/ACC/AHA Expert Consensus Statement on the Use of Implantable Cardioverter-Defibrillator Therapy in Patients Who Are Not Included or Not Well Represented in Clinical Trials | Circulation Search Hello Guest! Login to your account Email Password Keep me logged in Search March 2019 March 2019 March 2019 March 2019 March (...) 2019 February 2019 February 2019 February 2019 February 2019 January 2019 January 2019 January 2019 January 2019 January 2019 This site uses cookies. By continuing to browse this site you are agreeing to our use of cookies. Free Access article Share on Jump to Free Access article HRS/ACC/AHA Expert Consensus Statement on the Use of Implantable Cardioverter-Defibrillator Therapy in Patients Who Are Not Included or Not Well Represented in Clinical Trials , MD, FHRS , MD, FHRS , MD , MD , MD, FHRS

2014 American Heart Association

33. Is prescribing information from sales representatives balanced? (Full text)

Is prescribing information from sales representatives balanced? [91] Is prescribing information from sales representatives balanced? | Therapeutics Initiative Independent Healthcare Evidence > > [91] Is prescribing information from sales representatives balanced? Many Canadian physicians see pharmaceutical sales representatives (“drug detailers”) as a way to obtain free samples, keep up-to-date about new treatments, or as a friendly break from patient care. A common attitude to the promotional (...) , less familiar drugs. Promotional information is unlikely to meet that need. References Mintzes B, Lexchin J, Sutherland JM et al. Pharmaceutical sales representatives and patient safety: a comparative prospective study of information quality in Canada, France and the United States. J Gen Intern Med 2013; 28(10):1368-75. Strang DG, Gagnon M, Molloy DW et al. Development of a standardized, comprehensive “ideal drug detail”. Can J Clin Pharmacol 2001; 8(2):73-77. Health Canada. Regulation of Health

2014 Therapeutics Letter PubMed

34. Development of multi-criteria decision analysis (MCDA) framework for off-patent pharmaceuticals - an application on improving tender decision making in Indonesia. (Full text)

experts representing different stakeholder groups and decision-making bodies selected the final criteria, approved the scoring function for each criterion, and assigned weights to each criterion.An MCDA framework was proposed for OPP drug decision making in developing countries, which included price and 8 non-price criteria. Based on the pilot policy workshop 6 + 1 criteria were considered relevant for Indonesia: pharmaceutical price (40% weight), manufacturing quality (18.8%), equivalence (...) Development of multi-criteria decision analysis (MCDA) framework for off-patent pharmaceuticals - an application on improving tender decision making in Indonesia. Off-patent pharmaceuticals (OPPs) hold vital importance in meeting public health objectives, especially in developing countries where resources are limited. OPPs are comprised of off-patent originals, branded generics and unbranded generics; nonetheless, these products are not identical and often there are differences

2018 BMC health services research PubMed

35. Impact of demographic factors on the antidepressant effect: A patient-level data analysis from depression trials submitted to the Pharmaceuticals and Medical Devices Agency in Japan. (PubMed)

Impact of demographic factors on the antidepressant effect: A patient-level data analysis from depression trials submitted to the Pharmaceuticals and Medical Devices Agency in Japan. A substantial and variable placebo response can cause unreliable findings in clinical trials designed to demonstrate the efficacy of antidepressants, and the high rate of failed trials represents a major obstacle in the development of new drugs for major depressive disorder (MDD). However, the influence (...) of demographic and symptom factors on the antidepressant effect remains to be established. The purpose of this study was to estimate the magnitude of this influence. A patient-level meta-analysis of data from double-blind, randomized, placebo-controlled trials involving the use of antidepressants for adults with MDD was performed. Data from five confirmatory trials evaluating the efficacy of four antidepressants that were submitted to the Pharmaceuticals and Medical Devices Agency (PMDA) to support new drug

2018 Journal of psychiatric research

36. Direct-to-Consumer Broadcast Advertisements for Pharmaceuticals: Off-Label Promotion and Adherence to FDA Guidelines. (PubMed)

Direct-to-Consumer Broadcast Advertisements for Pharmaceuticals: Off-Label Promotion and Adherence to FDA Guidelines. Direct-to-consumer (DTC) advertisements for prescription drugs in the United States are regulated by the Food and Drug Administration (FDA). Off-label promotion, or the advertisement of a drug for an indication not approved by the FDA, is prohibited. Our objective was to examine the presence of off-label promotion in broadcast DTC ads and to assess their adherence to FDA (...) in presentation of risks and benefits.Our sample included 97 unique DTC ads, representing 60 unique drugs and 67 unique drug-indication combinations. No ads described drug risks quantitatively, whereas drug efficacy was presented quantitatively in 25 (26%) ads. Thirteen (13%) ads, all for diabetes medications, suggested off-label uses for weight loss and blood pressure reduction. The most commonly advertised drugs were indicated for the treatment of inflammatory conditions (n = 12; 18%), diabetes or diabetic

2018 Journal of General Internal Medicine

37. Individualized Pharmaceutical-care for Inpatients With Cancer Pain

pharmaceutical care. Quality of life is assessed using EuroQol- 5 Dimension (EQ-5D). It is a questionnaire to measure quality of life. It contains 5 domains: Mobility; Self-care; Usual activity; Pain; Anxiety/depression. It also contains a visual analogue scale. Weights are used to score the responses to the 5 domains, with scores ranging from 0 to 1 (where a score of 1 represents a perfect state). For the visual analogue scale, participants draw a line from a box to the point on the thermometer-like scale (...) Individualized Pharmaceutical-care for Inpatients With Cancer Pain Individualized Pharmaceutical-care for Inpatients With Cancer Pain - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Individualized

2018 Clinical Trials

38. The Quality of Medicines Used in Children and Supplied by Private Pharmaceutical Wholesalers in Kinshasa, Democratic Republic of Congo: A Prospective Survey. (Full text)

The Quality of Medicines Used in Children and Supplied by Private Pharmaceutical Wholesalers in Kinshasa, Democratic Republic of Congo: A Prospective Survey. Poor-quality medicines are a threat to public health in many low- and middle-income countries, and prospective surveys are needed to inform corrective actions. Therefore, we conducted a cross-sectional survey on a sample of products used for children and available in the private market in Kinshasa, Democratic Republic Congo: amoxicillin (...) (AX) and artemether/lumefantrine (AL), powders for suspension, and paracetamol (PC) tablets 500 mg. Overall, 417 products were covertly purchased from 61 wholesalers. To obtain a representative sample, the products were weighted on their market shares and a subset of 239 samples was randomly extracted to undergo in-depth visual inspection locally, and they were chemically assessed at two accredited laboratories in Belgium. Samples were defined of "poor-quality" if they failed to comply

2018 American Journal of Tropical Medicine & Hygiene PubMed

39. Would You Use It With a Seal of Approval? Important Attributes of 2,4-Dinitrophenol (2,4-DNP) as a Hypothetical Pharmaceutical Product (Full text)

Would You Use It With a Seal of Approval? Important Attributes of 2,4-Dinitrophenol (2,4-DNP) as a Hypothetical Pharmaceutical Product 2,4-Dinitrophenol (2,4-DNP) is an effective but highly dangerous fat burner, not licensed for human consumption. Death cases reported for 2,4-DNP overdose, particularly among young adults, have raised concerns about the ineffective regulatory control, lack of education and risks associated with impurity, and the unknown concentration of 2,4-DNP purchased (...) on the Internet.Using a sequential mixed method design and based on a hypothetical scenario as if 2,4-DNP was a licensed pharmaceutical drug, first we conducted a qualitative study to explore what product attributes people consider when buying a weight-loss aid. Focus group interviews with six females and three males (mean age = 21.6 ± 1.8 years) were audiorecorded, transcribed verbatim, and subjected to thematic analysis. Sixteen attributes were identified for the Best-Worst Scale (BWS) in the quantitative survey

2018 Frontiers in Psychiatry PubMed

40. Weaving the health and pharmaceutical care agenda through the themes of the commonwealth heads of government meeting (CHOGM), London 2018 (Full text)

Weaving the health and pharmaceutical care agenda through the themes of the commonwealth heads of government meeting (CHOGM), London 2018 The biennial Commonwealth Heads of Government Meeting (CHOGM) this year is based around four key themes: prosperity, fairness, sustainability and security. This is an opportune time to consider the role of pharmacists in healthcare delivery, and particularly their contribution to achieving the United Nations Sustainable Development Goals (SDGs). As a member (...) of the Commonwealth Health Professions Alliance (CHPA), the Commonwealth Pharmacists Association (CPA) has been working to ensure that pharmacy-related aspects of health are represented in the advocacy papers submitted by Civil Society. Echoing the CHPA's priorities around SDG 3 (health) and the attainment of sustainable universal health coverage (UHC), the CPA has been raising the profile of key priorities for our members, including: addressing the shortage of healthcare workers (with an emphasis on pharmacists

2018 Journal of pharmaceutical policy and practice PubMed

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>